3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
19
Carcinoma, Non-Small-Cell Lung
19
Breast Neoplasms
17
Lung Neoplasms
15
Colonic Neoplasms
11
Head and Neck Neoplasms
9
Rectal Neoplasms
7
Glioblastoma
5
Prostatic Neoplasms
4
Precancerous Conditions
4
Mouth Neoplasms
4
Esophageal Neoplasms
4
Central Nervous System Neoplasms
4
Adenomatous Polyposis Coli
4
Uterine Cervical Neoplasms
3
Unspecified Adult Solid Tumor, Protocol Specific
3
Sarcoma
3
Neuroblastoma
3
Neoplasms
3
Liver Neoplasms
3
Gliosarcoma
3
Glioma
3
Urinary Bladder Neoplasms
2
Triple Negative Breast Neoplasms
2
Smoking
2
Salivary Gland Neoplasms
2
Pancreatic Neoplasms
2
Oropharyngeal Neoplasms
2
Nasopharyngeal Neoplasms
2
Multiple Myeloma
2
Interventions
Melphalan
3
sargramostim
1
romidepsin
1
montanide ISA 51
1
keyhole-limpet hemocyanin
1
detox adjuvant
1
Ursodeoxycholic Acid
1
Thalidomide
1
Streptozocin
1
Mercaptopurine
1
Leucovorin
1
Interleukin-2
1
Floxuridine
1
FANG vaccine
1
Docetaxel
1
Celecoxib
1
Carmustine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Genetic Diseases, Inborn
×
Celecoxib
×
Clear all
NCT00808743
2013-05-16
PreDuoFAP
Radboud University Medical Center
Phase 2/3
Completed
37 enrolled